Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.

Ann Oncol · 2019 · PMC6927320 · PMID 31560066

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significanceP = 0.07so close (0.05 < p ≤ 0.1)

At IA1, the OS HR was 0.70, favoring apalutamide, but did not reach statistical significance ( P = 0.07) [ 10 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.